Lipigon Pharmaceuticals signs USD 91 million deal with Leaderna Therapeutics
Lipigon Pharmaceuticals from Umeå is celebrating the signing of a development and license agreement for its clinical-stage drug candidate Lipisense® with Leaderna Therapeutics worth an estimated USD 91 million.
“We are delighted with this agreement and look forward to working with Leaderna on the future development of Lipisense®”, says Stefan K Nilsson, CEO of Lipigon. The new agreement specifically involves the development and licensing of the drug in Greater China.